CDK1 and invasive breast carcinoma: To investigate the clinical significance of the upstream (PLK1) and downstream (CDK1) modulators of FOXC2, we analyzed the data from a cohort of patients with invasive breast cancers following taxane-anthracycline chemotherapy39.